At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 122 enrolled
Drug / intervention
Brexpiprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multicenter, Open-label, Interventional Trial to Assess the Effects on Engagement of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy for the Treatment of Adults With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Apr 5, 2021·Updated Feb 2, 2024
In Brief
A Phase 4 clinical trial evaluating Brexpiprazole for Major Depressive Disorder. Completed, enrolled 122 participants across 1 site.
Detailed Summary
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada
CollaboratorsLundbeck Canada Inc., Otsuka Canada Pharmaceutical Inc.
Timeline
Phase 4CompletedFinished
20222023202420252026
Enrollment StartApr 2021
First PostedApr 2021
Primary CompletionMay 2022
TodayJul 2026
First PostedApr 5, 2021
Enrollment StartApr 1, 2021
Primary CompletionMay 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago
Interventions
Brexpiprazoledrug
Oral brexpiprazole tablets as adjunctive therapy to ADT